All Articles

A pivotal partnership between WeInfuse and Trial IQ leverages AI to bring clinical trials to local infusion centers, signaling a major shift in drug development.

Tyrur Holdings' new pact with UBS isn't just another partnership. It's a masterclass in leveraging legacy power for modern agility in a volatile world.

A two-year delay for Carbios' biorecycling plant in China isn't a failure, but a harsh lesson in scaling innovation. Here's what it means for the future.

That $1 trillion pile of unused loyalty points may soon be spendable cash. A tech firm, backed by The Points Guy, is turning rewards into a currency.

A top national law firm opens in Fort Worth, but the real story is its leader—a hometown hero. This is how institutional innovation meets deep community roots.

A record-breaking loan for a Four Seasons project with no hotel signals a profound shift in how the ultra-wealthy live, and how Austin is being remade.

Signal's encryption is world-class, but it can't stop human error. A new layer of 'data-centric' security aims to protect sensitive data after it's stolen.

A landmark U.S. collaboration between Heron Power and LG aims to solve the energy crisis sparked by AI, pairing next-gen transformers with domestic batteries.

A new Sunnyvale service claims it can turn AI hardware concepts into investor-ready demos in just 21 days, attacking the notorious development bottleneck.

The refrigerated section is no longer just for basics. It's a hub for innovation where protein, convenience, and global flavors are reshaping our diets.

NexTel Medical acquires two telehealth firms for an instant $135K in monthly revenue, aiming to launch its Maxasome™ exosome therapies to 1,850 clinics.

Static PDFs and fragmented sales pitches are failing. A new class of AI-guided platforms is helping buyers build trust on their own terms. What does this mean?

With FDA clearance for its MagSense® trial, Imagion Biosystems' molecular MRI could change how we see cancer, offering a non-radioactive, high-precision future.

AM Best's negative outlook for a Pennsylvania insurer reveals a deeper crisis. A 16.5% surplus loss from weather is a harbinger for the entire sector.

As Vallarta Supermarkets expands to Merced, it reveals a masterclass in durable growth: a strategy built not on price wars, but on deep community integration.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Keysight's new RF signal analyzers promise to slash development time for 5G and beyond. But are they the definitive answer to the complexity crisis facing engineers?

Trillium's sale of its nuclear valve unit to Framatome isn't just a divestment; it's a strategic realignment reshaping the critical infrastructure landscape.

A small startup just raised $4M to solve the biggest problem in tech: making AR glasses affordable. Their secret isn't a new gadget, but a materials science breakthrough.

A new platform, Risk Monitor, automates the tracking of permits, community sentiment, and environmental data to help developers stay ahead of project-killing risks.